{
    "Clinical Trial ID": "NCT00291694",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Celecoxib",
        "  Randomized to receive celecoxib daily for 12 months",
        "INTERVENTION 2: ",
        "  Placebo",
        "  Randomized to receive placebo daily for 12 months"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  women who have a high risk of breast cancer",
        "  older than 18 years",
        "Exclusion Criteria:",
        "  anticoagulants",
        "  marked breast tenderness",
        "  pregnant or within twelve months of breast feeding/childbirth"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67",
        "  Immunocytochemical staining of breast epithelial cells. Positive cells reflect proliferative activity.",
        "  Time frame: Baseline and 12 months",
        "Results 1: ",
        "  Arm/Group Title: Celecoxib",
        "  Arm/Group Description: Randomized to receive celecoxib daily for 12 months",
        "  Overall Number of Participants Analyzed: 43",
        "  Median (Full Range)",
        "  Unit of Measure: percentage of cells staining positive  -1.2        (-18 to 14.8)",
        "Results 2: ",
        "  Arm/Group Title: Placebo",
        "  Arm/Group Description: Randomized to receive placebo daily for 12 months",
        "  Overall Number of Participants Analyzed: 21",
        "  Median (Full Range)",
        "  Unit of Measure: percentage of cells staining positive  -2.0        (-8.8 to 12.2)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/43 (0.00%)",
        "Adverse Events 2:",
        "  Total: "
    ]
}